1. Reconciled Cardiovascular and Thrombosis Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 2,184 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 831 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 799 / 245 | 23.47% closed-trial attrition ratio across 1,044 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 58 / 16 / 19 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 75.2% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Cardiovascular and Thrombosis
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| EMS | Biopharma Industry | 47 | 13 | 8 | 0 |
| University of Sao Paulo General Hospital | Academic / Institutional Sponsor | 34 | 6 | 6 | 0 |
| Hanmi Pharmaceutical Company Limited | Biopharma Industry | 29 | 8 | 20 | 0 |
| Arrowhead Pharmaceuticals | Biopharma Industry | 28 | 10 | 15 | 0 |
| Chong Kun Dang Pharmaceutical | Biopharma Industry | 27 | 3 | 15 | 0 |
| Population Health Research Institute | Academic / Institutional Sponsor | 23 | 10 | 11 | 0 |
| Shenzhen Salubris Pharmaceuticals Co | Biopharma Industry | 23 | 9 | 13 | 0 |
| University of Monastir | Academic / Institutional Sponsor | 21 | 7 | 10 | 0 |
| Addpharma | Biopharma Industry | 16 | 4 | 11 | 0 |
| Insmed Incorporated | Biopharma Industry | 16 | 5 | 9 | 0 |
| Ottawa Heart Institute Research | Academic / Institutional Sponsor | 16 | 11 | 4 | 0 |
| Beijing Suncadia Pharmaceuticals Co | Biopharma Industry | 15 | 7 | 8 | 0 |
3. Representative Multi-Center Phase II & III Cardiovascular and Thrombosis Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07575672 | Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase III | RECRUITING |
| NCT07303777 | Efficacy, Safety, and PopPK Profile of ABP-745 in Patients With Atherosclerosis | Atom Therapeutics Co | Phase II | RECRUITING |
| NCT06475781 | Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward) | Foresee Pharmaceuticals Co | Phase II | RECRUITING |
| NCT07613294 | A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk | Eli Lilly and Company | Phase III | RECRUITING |
| NCT06736574 | Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Cytokinetics | Phase III | RECRUITING |
| NCT06772168 | Evaluate the Efficacy and Safety of CMG190303 in Patients With Type 2 Diabetes and Dyslipidemia | CMG Pharmaceutical Co | Phase III | RECRUITING |
| NCT07687186 | Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre | Tasly Pharmaceutical Group Co | Phase III | RECRUITING |
| NCT06563895 | Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Eidos Therapeutics, a BridgeBio company | Phase III | RECRUITING |
| NCT07771465 | A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Kardigan | Phase III | RECRUITING |
| NCT07210723 | A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Kardigan | Phase II/III | RECRUITING |
| NCT07192952 | A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Bayer | Phase III | RECRUITING |
| NCT07188805 | A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ve | Bayer | Phase III | RECRUITING |
| NCT07448038 | A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events | Roche / Genentech | Phase II | RECRUITING |
| NCT07285655 | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Liquidia Technologies | Phase III | RECRUITING |
| NCT05179876 | A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | Johnson & Johnson / Janssen | Phase III | RECRUITING |
| NCT05836987 | The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Johns Hopkins University | Phase III | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Neurology, Psychiatry, and Pain, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.